FRDD

Forensically-Relevant Drug Database

NPS Discover

Description

Preferred Drug Name

5,6-Dichloro Brorphine

Brief Description

5,6-Dichloro brorphine is a novel synthetic opioid characterized as an “orphine” analogue and bears structural similarity to other benzimidazolones (e.g., brorphine, chlorphine, 5,6-dichloro desmethylchlorphine). 5,6-Dichloro brorphine was originally synthesized and researched for use for analgesia with a suggested large therapeutic window and decrease of severe adverse side effects (e.g., respiratory depression). 5,6-Dichloro brorphine was first identified by our laboratory in November 2025 and confirmed after acquiring standard reference material.

Structure


Nomenclature

Formal Name (IUPAC)

3-[1-[1-(4-bromophenyl)ethyl]-4-piperidyl]-5,6-dichloro-1H-benzimidazol-2-one

Synonyms

SR-14968

Identifiers

CAS Numbers

2133455-40-8

Chemistry

Chemical Formula

C20H20BrCl2N3O

Molecular Mass

469.20

Molecular Ion

467

Exact Mass

468.024

SMILES

BrC1=CC=C(C(C)N2CCC(N3C(NC4=C3C=C(Cl)C(Cl)=C4)=O)CC2)C=C1

InChI String

InChI=1S/C20H20BrCl2N3O/c1-12(13-2-4-14(21)5-3-13)25-8-6-15(7-9-25)26-19-11-17(23)16(22)10-18(19)24-20(26)27/h2-5,10-12,15H,6-9H2,1H3,(H,24,27)

InChI Key

DJSSLECNUQMYKG-UHFFFAOYSA-N

GCMS Analytics

Lab

CFSRE (Willow Grove, PA)

Comments

Sample Preparation:

Drug Materials: Dilution in methanol or acid / base extraction

Drug Standards: Dilution in methanol

Instrument:Agilent 5975 Series GC/MSD System
Column:Agilent J&W DB-1 (12 m x 200 µm x 0.33 µm)
Carrier Gas:Helium (Flow: 1.46 mL/min)
Temperatures:

Injection Port: 265 °C

Transfer Line: 300 °C

MS Source: 230 °C

MS Quad: 150 °C

Oven Program: 50 °C for 0 min, 30 °C/min to 340 °C for 2.3 min

Injection Parameters:Injection Type: Splitless, Injection Volume: 1 µL
MS Parameters:Mass Scan Range: 40-550 m/z

 

Images

Fragments

82
104
183
284
169

HRMS Analytics

Lab

CFSRE (Willow Grove, PA)

Comments

Sample Preparation:

Toxicology Samples: Liquid-liquid extraction

Drug Materials: Dilution of sample in mobile phase

Instrument:

Sciex TripleTOF® 5600+, Shimadzu Nexera XR UHPLC

Sciex X500R, Sciex ExionLC

Column:Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm)
Mobile Phase:

A: Ammonium formate (10 mM, pH 3.0)

B: Methanol/acetonitrile (50:50)

Flow rate: 0.4 mL/min

Gradient:Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min
Temperatures:

Autosampler: 15 °C

Column Oven: 30 °C

Source Heater: 600 °C

Injection Parameters:Injection Volume: 10 µL
QTOF Parameters:

TOF MS Scan Range: 100-510 Da

Precursor Isolation: SWATH® acquisition (27 windows)

Fragmentation: Collison Energy Spread (35±15 eV)

MS/MS Scan Range: 50-510 Da

 

Images

Fragments

182.9804
286.0519
470.0217
84.0813
104.0623

Drug Origins and Uses

Drug Origins and Uses

Illicit, Synthetic

Biological Effects

Biological Effects

Analgesic, Depressant, Sedative/Hypnotic

Target Receptor or Neurotransmitter

Target Receptor or Neurotransmitter

MOR

Pharmacodynamics

Pharmacodynamics

Agonist

Drug Control

US Controlled Substance Schedule

Not Controlled


Pharmacology Literature

Source

Scripps Research

Title

Search for safer pain relief advances with new engineered compounds

Reference Link


Source

International Journal of Molecular Sciences

Title

Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles

Reference Link


Source

Cell

Title

Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics

Reference Link


Source

Proceedings of the National Academy of Sciences

Title

G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists

Reference Link


Source

Pharmaceutics

Title

Comparison of an Addictive Potential of μ-Opioid Receptor Agonists with G Protein Bias: Behavioral and Molecular Modeling Studies

Reference Link


Published January 27, 2026